Evaluation of the in vitro activity of eravacycline against a broad spectrum of recent clinical anaerobic isolates [PublishAheadOfPrint]

The novel fluorocycline antibiotic, eravacycline, is in development for the treatment of serious infections caused by susceptible and multidrug-resistant (MDR) aerobic and anaerobic Gram-negative and Gram-positive pathogens. Eravacycline and 11 comparator antibiotics were tested against recent anaerobic clinical isolates, including MDR Bacteroides spp. and Clostridium difficile. Eravacycline was potent in vitro against all the isolates tested, including strains with tetracycline-specific resistance determinants and MDR anaerobic pathogens resistant to carbapenems and/or β-lactam/β-lactamase inhibitor combinations.

http://ift.tt/2sZqcT7